vs

Side-by-side financial comparison of Bausch & Lomb Corp (BLCO) and RXO, Inc. (RXO). Click either name above to swap in a different company.

RXO, Inc. is the larger business by last-quarter revenue ($1.5B vs $1.4B, roughly 1.0× Bausch & Lomb Corp). RXO, Inc. runs the higher net margin — -3.1% vs -4.1%, a 1.0% gap on every dollar of revenue. On growth, Bausch & Lomb Corp posted the faster year-over-year revenue change (9.8% vs -11.9%). Bausch & Lomb Corp produced more free cash flow last quarter ($60.0M vs $-9.0M). Over the past eight quarters, RXO, Inc.'s revenue compounded faster (26.8% CAGR vs 13.1%).

Bausch & Lomb is an American-Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.

RXO, Inc. is a leading transportation and logistics solutions provider headquartered in the United States. Its core service portfolio includes freight brokerage, last-mile delivery for heavy and bulky goods, managed transportation services, and end-to-end supply chain optimization support, primarily catering to clients across the North American manufacturing, retail, and e-commerce segments.

BLCO vs RXO — Head-to-Head

Bigger by revenue
RXO
RXO
1.0× larger
RXO
$1.5B
$1.4B
BLCO
Growing faster (revenue YoY)
BLCO
BLCO
+21.6% gap
BLCO
9.8%
-11.9%
RXO
Higher net margin
RXO
RXO
1.0% more per $
RXO
-3.1%
-4.1%
BLCO
More free cash flow
BLCO
BLCO
$69.0M more FCF
BLCO
$60.0M
$-9.0M
RXO
Faster 2-yr revenue CAGR
RXO
RXO
Annualised
RXO
26.8%
13.1%
BLCO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLCO
BLCO
RXO
RXO
Revenue
$1.4B
$1.5B
Net Profit
$-58.0M
$-46.0M
Gross Margin
Operating Margin
8.0%
-2.9%
Net Margin
-4.1%
-3.1%
Revenue YoY
9.8%
-11.9%
Net Profit YoY
-1833.3%
-84.0%
EPS (diluted)
$-0.16
$-0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLCO
BLCO
RXO
RXO
Q4 25
$1.4B
$1.5B
Q3 25
$1.3B
$1.4B
Q2 25
$1.3B
$1.4B
Q1 25
$1.1B
$1.4B
Q4 24
$1.3B
$1.7B
Q3 24
$1.2B
$1.0B
Q2 24
$1.2B
$930.0M
Q1 24
$1.1B
$913.0M
Net Profit
BLCO
BLCO
RXO
RXO
Q4 25
$-58.0M
$-46.0M
Q3 25
$-28.0M
$-14.0M
Q2 25
$-62.0M
$-9.0M
Q1 25
$-212.0M
$-31.0M
Q4 24
$-3.0M
$-25.0M
Q3 24
$4.0M
$-243.0M
Q2 24
$-151.0M
$-7.0M
Q1 24
$-167.0M
$-15.0M
Operating Margin
BLCO
BLCO
RXO
RXO
Q4 25
8.0%
-2.9%
Q3 25
7.4%
-0.5%
Q2 25
-0.9%
Q1 25
-7.3%
-2.1%
Q4 24
6.8%
-1.4%
Q3 24
3.6%
-1.9%
Q2 24
2.1%
Q1 24
0.5%
-1.3%
Net Margin
BLCO
BLCO
RXO
RXO
Q4 25
-4.1%
-3.1%
Q3 25
-2.2%
-1.0%
Q2 25
-4.9%
-0.6%
Q1 25
-18.6%
-2.2%
Q4 24
-0.2%
-1.5%
Q3 24
0.3%
-23.4%
Q2 24
-12.4%
-0.8%
Q1 24
-15.2%
-1.6%
EPS (diluted)
BLCO
BLCO
RXO
RXO
Q4 25
$-0.16
$-0.28
Q3 25
$-0.08
$-0.08
Q2 25
$-0.18
$-0.05
Q1 25
$-0.60
$-0.18
Q4 24
$-0.00
$-0.17
Q3 24
$0.01
$-1.81
Q2 24
$-0.43
$-0.06
Q1 24
$-0.48
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLCO
BLCO
RXO
RXO
Cash + ST InvestmentsLiquidity on hand
$383.0M
$17.0M
Total DebtLower is stronger
$5.0B
$387.0M
Stockholders' EquityBook value
$6.4B
$1.5B
Total Assets
$14.0B
$3.3B
Debt / EquityLower = less leverage
0.78×
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLCO
BLCO
RXO
RXO
Q4 25
$383.0M
$17.0M
Q3 25
$310.0M
$25.0M
Q2 25
$266.0M
$18.0M
Q1 25
$202.0M
$16.0M
Q4 24
$305.0M
$35.0M
Q3 24
$329.0M
$55.0M
Q2 24
$285.0M
$7.0M
Q1 24
$315.0M
$7.0M
Total Debt
BLCO
BLCO
RXO
RXO
Q4 25
$5.0B
$387.0M
Q3 25
$5.0B
$387.0M
Q2 25
$5.0B
$387.0M
Q1 25
$4.8B
$387.0M
Q4 24
$4.8B
$351.0M
Q3 24
$4.6B
$352.0M
Q2 24
$4.6B
$370.0M
Q1 24
$4.6B
$351.0M
Stockholders' Equity
BLCO
BLCO
RXO
RXO
Q4 25
$6.4B
$1.5B
Q3 25
$6.4B
$1.6B
Q2 25
$6.4B
$1.6B
Q1 25
$6.4B
$1.6B
Q4 24
$6.5B
$1.6B
Q3 24
$6.6B
$1.7B
Q2 24
$6.5B
$579.0M
Q1 24
$6.7B
$582.0M
Total Assets
BLCO
BLCO
RXO
RXO
Q4 25
$14.0B
$3.3B
Q3 25
$13.8B
$3.2B
Q2 25
$13.8B
$3.2B
Q1 25
$13.4B
$3.3B
Q4 24
$13.5B
$3.4B
Q3 24
$13.5B
$3.4B
Q2 24
$13.3B
$1.8B
Q1 24
$13.3B
$1.8B
Debt / Equity
BLCO
BLCO
RXO
RXO
Q4 25
0.78×
0.25×
Q3 25
0.77×
0.24×
Q2 25
0.77×
0.24×
Q1 25
0.76×
0.24×
Q4 24
0.74×
0.22×
Q3 24
0.70×
0.21×
Q2 24
0.71×
0.64×
Q1 24
0.69×
0.60×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLCO
BLCO
RXO
RXO
Operating Cash FlowLast quarter
$136.0M
$7.0M
Free Cash FlowOCF − Capex
$60.0M
$-9.0M
FCF MarginFCF / Revenue
4.3%
-0.6%
Capex IntensityCapex / Revenue
5.4%
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-66.0M
$-8.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLCO
BLCO
RXO
RXO
Q4 25
$136.0M
$7.0M
Q3 25
$137.0M
$23.0M
Q2 25
$35.0M
$23.0M
Q1 25
$-25.0M
$-2.0M
Q4 24
$22.0M
$-7.0M
Q3 24
$154.0M
$-7.0M
Q2 24
$15.0M
$-5.0M
Q1 24
$41.0M
$7.0M
Free Cash Flow
BLCO
BLCO
RXO
RXO
Q4 25
$60.0M
$-9.0M
Q3 25
$63.0M
$9.0M
Q2 25
$-54.0M
$9.0M
Q1 25
$-135.0M
$-17.0M
Q4 24
$-70.0M
$-19.0M
Q3 24
$94.0M
$-18.0M
Q2 24
$-57.0M
$-16.0M
Q1 24
$-26.0M
$-4.0M
FCF Margin
BLCO
BLCO
RXO
RXO
Q4 25
4.3%
-0.6%
Q3 25
4.9%
0.6%
Q2 25
-4.2%
0.6%
Q1 25
-11.9%
-1.2%
Q4 24
-5.5%
-1.1%
Q3 24
7.9%
-1.7%
Q2 24
-4.7%
-1.7%
Q1 24
-2.4%
-0.4%
Capex Intensity
BLCO
BLCO
RXO
RXO
Q4 25
5.4%
1.1%
Q3 25
5.8%
1.0%
Q2 25
7.0%
1.0%
Q1 25
9.7%
1.0%
Q4 24
7.2%
0.7%
Q3 24
5.0%
1.1%
Q2 24
5.9%
1.2%
Q1 24
6.1%
1.2%
Cash Conversion
BLCO
BLCO
RXO
RXO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
38.50×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLCO
BLCO

Overthe Counter Products$489.0M35%
Pharmaceuticals$378.0M27%
Other$263.0M19%
Surgical$249.0M18%
Brandedand Other Generic Products$14.0M1%
Other Revenues$3.0M0%
Pharmaceutical Products$2.0M0%

RXO
RXO

Retail Sector$546.0M37%
Last Mile$298.0M20%
Food And Beverage Sector$225.0M15%
Other Sector$185.0M13%
Managed Transportation$133.0M9%
Automotive Sector$93.0M6%

Related Comparisons